Visium Asset Management’s Kyntra Bio KYNB Stock Holding History

Visium Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-94,550	Closed	-$50.3M	–	398
2016 Q1	$50.3M	Buy	94,550 +13,273	+16%	+$6.61M	0.86%	20
2015 Q4	$61.9M	Buy	81,277 +833	+1%	+$553K	0.93%	18
2015 Q3	$44.1M	Buy	80,444 +17,638	+28%	+$10.7M	0.6%	25
2015 Q2	$36.9M	Buy	62,806 +29,870	+91%	+$17.4M	0.52%	35
2015 Q1	$25.8M	Buy	32,936 +1,388	+4%	+$1.08M	0.38%	48
2014 Q4	$21.6M	Buy	+31,548	New	+$20.3M	0.3%	57

Other funds holding KYNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Visium Asset Management's KYNB Position: Q2 2016 in Review

Visium Asset Management sold out of Kyntra Bio (KYNB) in Q2 2016, closing a stake of 94,550 shares — an estimated $50.3M sold.

Visium Asset Management first reported a position in KYNB in Q4 2014 and held it in 6 quarters. The position peaked at $61.9M in Q4 2015. 146 funds tracked by Wall St. Rank hold KYNB as of Q2 2016.

Visium Asset Management reported no remaining Kyntra Bio position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 94,550 Kyntra Bio shares in Q2 2016, an estimated $50.3M.
Visium Asset Management first reported a position in Kyntra Bio in Q4 2014 and held it in 6 quarters.
Visium Asset Management's Kyntra Bio position peaked at $61.9M in Q4 2015.
146 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.